Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms Abstract #542

Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.
Aim(s): To share clinical and diagnostic data for best decision-making according to the existing ENETS Guidelines.
Materials and methods: According to the indications for ENETS Centers of Excellence, meetings with experts in Endocrinology, Endoscopy, Nuclear Medicine, Oncology, Pathology, Radiology and Surgery are held; interactive computer-assisted presentation of three or four cases each time presented by one representative of the caring equipe; electronic reports written, circulated and stored; descriptive statistics for data analysis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#170 Swiss Neuroendocrine Tumor (SwissNET) registry: Results after 30 Months
Introduction: The Swiss registry for NETs (SwissNET) was established in 2008 to improve epidemiological data on NET patients in Switzerland. Here the results after 30 months of follow-up are presented.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christoph Stettler
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#303 Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location
Introduction: We report an uncommon case of pancreatic metastases from a bronchial atypical carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#397 Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
Introduction: To improve epidemiological data on patients with neuroendocrine tumors (NETs) in Switzerland, the Swiss registry for NETs (SwissNET) was established in 2008. Here we present the current state of the registry in 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Christoph Stettler
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team